Francesco Montorsi

Francesco Montorsi

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1738 publications

Re: Alexander D. Sherry, Cara Haymaker, Shuqi Wang, et al. Addition of Metastasis-directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02856.

Re: Alexander D. Sherry, Cara Haymaker, Shuqi Wang, et al. Addition of Metastasis-directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO-25-02856.

Journal: European urology
Published: August 13, 2026

Patient selection for prostate cancer focal therapy guided by mpMRI-PSMA PET concordance and pathology review.

Patient selection for prostate cancer focal therapy guided by mpMRI-PSMA PET concordance and pathology review.

Journal: BJU international
Published: August 12, 2026

Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery.

Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery.

Journal: Nature reviews. Urology
Published: August 04, 2026

Re: Chernysheva D, Di Bello F, Avesani G et al. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol 2026; S0302-2838(26)02233-5.

Re: Chernysheva D, Di Bello F, Avesani G et al. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol 2026; S0302-2838(26)02233-5.

Journal: European urology
Published: July 24, 2026

Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.

Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.

Journal: European urology
Published: July 20, 2026

Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.

Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.

Journal: BJU international
Published: July 08, 2026

Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer.

Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer.

Journal: Current urology reports
Published: July 06, 2026

Robotic versus laparoscopic adrenalectomy for adrenocortical carcinoma: A national cancer database analysis.

Robotic versus laparoscopic adrenalectomy for adrenocortical carcinoma: A national cancer database analysis.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: July 04, 2026

Re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-412.

Re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-412.

Journal: European urology oncology
Published: July 03, 2026

Re: Bhatia S, Bhatia A, Richardson A, et al. Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80-250 cc: the hope trial outcome at 1 year. World J Urol. 2026; 44:87.

Re: Bhatia S, Bhatia A, Richardson A, et al. Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80-250 cc: the hope trial outcome at 1 year. World J Urol. 2026; 44:87.

Journal: World journal of urology
Published: June 30, 2026

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center.

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center.

Journal: World journal of urology
Published: June 19, 2026

Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4.

Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4.

Journal: European urology
Published: June 19, 2026
Showing 1-12 of 1,738

Last Updated: 09/26/2026